Project: Secretoneurin (SN): a breakthrough blood biomarker for heart disease and sudden Cardiac Arrest risk
| Acronym | SeNCA (Reference Number: 11989) |
| Duration | 31/03/2018 |
| Project Topic | Secretoneurin (SN) is a novel biomarker that improves risk prediction in cardiovascular disease by reflecting additional pathophysiology to established risk indices. SeNCA will bring this innovation towards market entry by developing and validating a SN ELISA and by documenting that SN identifies patients with increased risk of ventricular arrhythmias. The assay will be launched as a Research use Only (RuO) version immediately after SeNCA and as CE-marked version 12 months post-project. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 8 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | CardiNor AS (CNOR) | Coordinator | Norway |
| 2 | AKERSHUS UNIVERSITETSSYKEHUS HF (AHUS) | Partner | Norway |
| 3 | Bioventix PLC (BIOV) | Partner | United Kingdom |
| 4 | Kaivogen OY (KAIV) | Partner | Finland |